Peter Thomson's most recent trade in Fulcrum Therapeutics Inc was a trade of 40,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 19, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Fulcrum Therapeutics Inc | Peter Thomson | VP Finance & Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2022 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Fulcrum Therapeutics Inc | Peter Thomson | VP Finance & Accounting | Purchase of securities on an exchange or from another person at price $ 9.00 per share. | 28 Jun 2021 | 2,300 | 2,300 (0%) | 0% | 9 | 20,700 | Common Stock |
| Fulcrum Therapeutics Inc | Peter Thomson | VP Finance & Accounting | Sale of securities on an exchange or to another person at price $ 14.72 per share. | 22 Feb 2021 | 5,000 | 15,212 (0%) | 0% | 14.7 | 73,582 | Common Stock |
| Fulcrum Therapeutics Inc | Peter Thomson | VP Finance & Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2021 | 5,000 | 50,471 | - | - | Stock Option (right to buy) | |
| Fulcrum Therapeutics Inc | Peter Thomson | VP Finance & Accounting | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 22 Feb 2021 | 5,000 | 20,212 (0%) | 0% | 7.8 | 39,200 | Common Stock |
| Fulcrum Therapeutics Inc | Peter Thomson | VP Finance & Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2021 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Fulcrum Therapeutics Inc | Peter Thomson | VP Finance & Accounting | Sale of securities on an exchange or to another person at price $ 14.00 per share. | 21 Jan 2021 | 6,607 | 15,212 (0%) | 0% | 14 | 92,498 | Common Stock |